HSF1 Pathway Inhibitor Clinical Candidate (CCT361814/NXP800) Developed from a Phenotypic Screen as a Potential Treatment for Refractory Ovarian Cancer and Other Malignancies
Elisa Pasqua, Swee Y. Sharp, N. Chessum, Angela Hayes, Loredana Pellegrino, Michael Tucker, Asadh Miah, Birgit Wilding, Lindsay E. Evans, Carl S. Rye, N. Yi Mok, Manjuan Liu, Alan T. Henley, Sharon Gowan, Emmanuel de Billy, Robert te Poele, Marissa Powers, Suzanne A. Eccles, Paul A. Clarke, Florence I. Raynaud, Paul Workman, Keith Jones, Matthew D. Cheeseman
Abstract
has now progressed to phase 1 clinical trial as a potential future treatment for refractory ovarian cancer and other malignancies.
Topics & Concepts
Ovarian cancerCancer researchCancerMalignancyChemistryOncologyPharmacologyInternal medicineMedicineHeat shock proteins researchDNA Repair MechanismsEndoplasmic Reticulum Stress and Disease